Sun Pharma Q1 PAT seen down 13% to Rs 489 cr (YoY)

Sun Pharmaceutical Industries is to announce its first quarter results. According to CNBC-TV18's estimates, the company's Q1FY12 revenues are seen up 22% to Rs 1709 crore versus Rs 1400 crore, year-on-year, YoY.

Its EBITDA is seen down 13% at Rs 524 crore versus Rs 600 crore.
Its OPM is seen 30.7% versus 43%.
The company's PAT is seen down 13% to Rs 489 crore versus Rs 564 crore, YoY.
Q1FY12 QoQ
The company Q1FY12 revenues are seen 17% to Rs 1709 crore versus Rs 1463 crore, quarter-on-quarter, QoQ.
Its EBITDA is seen up 18% to Rs 524 crore versus Rs 444 crore, QoQ
Its OPM is seen 30.7% versus 30.3%.
The company's PAT is seen up 10% to Rs 489 crore versus Rs 443 crore, QoQ